Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Paull

Showing results (61-70 of 63) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 63 results.
European Journal of Cancer (Oxford, England : 1990)|May 28, 2026
Dendrimer-nanoparticle (DEP) delivery of cabazitaxel (DEP-cabazitaxel): A first-in-human phase 1/2 trial in patients with advanced solid tumoursRobert H Jones, David J Pinato, Martin D Forster, et al.
Plos One|September 3, 2010
Structure activity relationship of dendrimer microbicides with dual action antiviral activityDavid Tyssen, Scott A Henderson, Adam Johnson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2025
Dendrimer-Nanoparticle (DEP) Delivery of Topoisomerase I Inhibitor, SN38 (DEP-SN38): Safety, Tolerability, and Preliminary Efficacy Study in Patients With Advanced Solid TumorsJia Liu, Anna R Minchom, Alastair Greystoke, et al.
Pageof 7

Showing results (61-70 of 63) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 63 results.
European Journal of Cancer (Oxford, England : 1990)|May 28, 2026
Dendrimer-nanoparticle (DEP) delivery of cabazitaxel (DEP-cabazitaxel): A first-in-human phase 1/2 trial in patients with advanced solid tumoursRobert H Jones, David J Pinato, Martin D Forster, et al.
Plos One|September 3, 2010
Structure activity relationship of dendrimer microbicides with dual action antiviral activityDavid Tyssen, Scott A Henderson, Adam Johnson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2025
Dendrimer-Nanoparticle (DEP) Delivery of Topoisomerase I Inhibitor, SN38 (DEP-SN38): Safety, Tolerability, and Preliminary Efficacy Study in Patients With Advanced Solid TumorsJia Liu, Anna R Minchom, Alastair Greystoke, et al.
Pageof 7